Results 101 to 110 of about 158,913 (343)

Safety and feasibility of Lin- cells administration to ALS patients : a novel view on humoral factors and miRNA profiles [PDF]

open access: yes, 2018
Therapeutic options for amyotrophic lateral sclerosis (ALS) are still limited. Great hopes, however, are placed in growth factors that show neuroprotective abilities (e.g., nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and vascular
Baumert, Bartłomiej   +12 more
core   +2 more sources

Implantable Drug Delivery Systems for Skeletal Muscles and Eyes

open access: yesAdvanced NanoBiomed Research, EarlyView.
This review highlights the different types of recent implantable drug delivery systems (IDDS) fabricated for a use with skeletal muscles, and with eyes. It presents the developments already made and the current research directions, showing the evolution of IDDS and their great diversity.
Serge Ostrovidov   +8 more
wiley   +1 more source

BAFF Index and CXCL13 levels in the cerebrospinal fluid associate respectively with intrathecal IgG synthesis and cortical atrophy in multiple sclerosis at clinical onset [PDF]

open access: yes, 2017
Background B lymphocytes are thought to play a relevant role in multiple sclerosis (MS) pathology. The in vivo analysis of intrathecally produced B cell-related cytokines may help to clarify the mechanisms of B cell recruitment and ...
Ermani, M.   +11 more
core   +1 more source

Analgesic efficacy of intrathecal fentanyl during the period of highest analgesic demand after cesarean section

open access: yesMedicine, 2016
Cesarean section (CS) is one of the most common surgical procedures in female patients. We aimed to evaluate the postoperative analgesic efficacy of intrathecal fentanyl during the period of greatest postoperative analgesic demand after CS.
W. Weigl   +6 more
semanticscholar   +1 more source

Switching disease‐modifying therapies in patients with spinal muscular atrophy: A systematic review on effectiveness outcomes

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
With multiple disease‐modifying therapies now available, treatment switching has become an important clinical consideration in the management of spinal muscular atrophy (SMA). While some switches are prompted by suboptimal clinical response, more commonly they are driven by treatment burden, convenience, or adverse events.
Andrej Belančić   +4 more
wiley   +1 more source

Identifying functional populations among the interneurons in laminae I-III of the spinal dorsal horn [PDF]

open access: yes, 2017
The spinal dorsal horn receives input from primary afferent axons, which terminate in a modality-specific fashion in different laminae. The incoming somatosensory information is processed through complex synaptic circuits involving excitatory and ...
Todd, Andrew J.
core   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló   +5 more
wiley   +1 more source

Intrathecal Therapy for Cancer-Related Pain

open access: yesPain medicine (Malden, Mass.), 2016
Objective. The increasing incidence of cancer survivorship has shifted treatment of cancer-related pain from short-term analgesia to long-term chronic pain management.
B. Bruel, A. Burton
semanticscholar   +1 more source

Intrathecal Drug Delivery Systems Survey: Trends in Utilization in Pain Practice

open access: yesJournal of Pain Research, 2022
Alaa Abd-Sayed,1 Kenneth Fiala,1 Jacqueline Weibstein,2 Pooja Chopra,3 Christopher Lam,4 Hemant Kalia,5 Navdeep Jassal,6 Amitabh Gulati,7 Dawood Sayed,4 Timothy Deer8 1Department of Anesthesiology, University of Wisconsin School of Medicine and Public ...
Abd-Sayed A   +9 more
doaj  

Delivery strategies of messenger RNA therapeutics for brain disorders

open access: yesBulletin of the Korean Chemical Society, EarlyView.
Thus, mRNA therapeutics offer a powerful new avenue for the treatment of brain diseases. This review examines strategies to bypass biological barriers, particularly the blood–brain barrier, and explores emerging delivery systems, such as direct intracerebral injection, intracerebroventricular injection, systemic delivery (including intravenous ...
Kounghwa Youn   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy